ERA 2025 Archives - Medical Conferences

Home > Nephrology > ERA 2025

Read the full Report (pdf)

European Renal Association 04–07 June 2025 Vienna, Austria

Featured articles

Letter from the Editor

Editor

Prof. John Sayer, Newcastle University, UK

Conference

ERA 2025

22 August 2025 15:49

Nefecon maintains kidney function regardless of baseline status over 24 months in IgA nephropathy

Presented By

Prof. Jonathan Barratt , University of Leicester, UK

Conference

ERA 2025

Type

Peer-reviewed article

22 August 2025 15:20

ERA 2025 Highlights Podcast

Presented By

Dr. Rachel Giles, Robert van den Heuvel, Medicom

Conference

ERA 2025

4 July 2025 14:06

Online First

New Frontiers in Cardiorenal Protection: SGLT2 Inhibitors and Emerging Therapies

Acute eGFR dip following empagliflozin initiation is not associated with acute kidney injury

Presented By

Dr Natalie Staplin , University of Oxford, UK

Conference

ERA 2025

Type

Peer-reviewed article

22 August 2025 14:56

Sibeprenlimab is an emerging treatment option for IgA nephropathy

Presented By

Prof. Vlado Perkovic , University of New South Wales, Australia

Conference

ERA 2025

Type

Peer-reviewed article

22 August 2025 14:55

Finerenone plus empagliflozin as a new potential combination in patients with type 2 diabetes and chronic kidney disease

Presented By

Prof. Johannes Mann , Friedrich Alexander University, Germany

Conference

ERA 2025

Type

Peer-reviewed article

22 August 2025 14:53

Large meta-analysis shows that empagliflozin slows kidney progression and reduces risk among patients with multiple diseases

Presented By

Prof. William Herrington , University of Oxford, UK

Conference

ERA 2025

Type

Peer-reviewed article

22 August 2025 14:51

Canagliflozin has a dose-dependent effect on cardiovascular outcomes in patients with type 2 diabetes

Presented By

Dr Elias Elenjickal, McGill University Health Centre, Canada

Conference

ERA 2025

Type

Peer-reviewed article

22 August 2025 14:49

Late-Breaking Nephrology Studies

Survival benefit from kidney transplantation depends on the donor source

Presented By

Prof. Rachel Hellemans , Antwerp University Hospital, Belgium

Conference

ERA 2025

Type

Peer-reviewed article

22 August 2025 16:14

Mineral receptor antagonists are not beneficial for patients undergoing dialysis

Presented By

Dr Lonnie Pyne , McMaster University, Canada

Conference

ERA 2025

Type

Peer-reviewed article

22 August 2025 15:18

Spironolactone is not useful in dialysis with cardiovascular risk

Presented By

Dr Michael Walsh , McMaster University, Canada

Conference

ERA 2025

Type

Peer-reviewed article

22 August 2025 15:16

Factor XI inhibition is not useful for end-stage kidney disease patients receiving haemodialysis

Presented By

Prof. Wolfgang Winkelmayer , Baylor College of Medicine, TX, USA

Conference

ERA 2025

Type

Peer-reviewed article

22 August 2025 15:02

ERA’s Top 10 Abstracts

Dialysis initiation is associated with high rates of polypharmacy, which do not decrease over time

Presented By

Ms Léa Faure , University of Bordeaux, France

Conference

ERA 2025

Type

Peer-reviewed article

22 August 2025 15:33

NefIgArd: Nefecon leads to sustained decline in proteinuria and eGFR stabilisation

Presented By

Prof. Jonathan Barratt , University of Leicester, UK

Conference

ERA 2025

Type

Peer-reviewed article

22 August 2025 15:32

Immune checkpoint inhibitor-induced acute interstitial nephritis characterised by distinct immunophenotypes with potentially different management

Presented By

Dr Idris Boudhabhay, Necker Hospital, France

Conference

ERA 2025

Type

Peer-reviewed article

22 August 2025 15:31

Pegcetacoplan is a treatment option for patients with C3G or IC-MPGN with nephrotic-range proteinuria

Presented By

Dr Antonio Mastrangelo , Policlinico of Milan, Italy

Conference

ERA 2025

Type

Peer-reviewed article

22 August 2025 15:30

Iptacopan improves mesenchymal and capillary glomerular C3 deposition in patients with C3 glomerulopathy

Presented By

Prof. Julia Weinmann-Menke, University of Mainz, Germany

Conference

ERA 2025

Type

Peer-reviewed article

22 August 2025 15:29

Ravulizumab improves long-term quality-of-life in atypical haemolytic uraemic syndrome

Presented By

Prof. David Kavanagh, Newcastle University, UK

Conference

ERA 2025

Type

Peer-reviewed article

22 August 2025 15:25

Lumasiran shows continued promise in infants and young children with primary hyperoxaluria type 1

Presented By

Dr Wesley Hayes , Great Ormond Street Hospital for Children NHS, UK

Conference

ERA 2025

Type

Peer-reviewed article

22 August 2025 15:22

Anti-PAPP-A antibody shows preclinical promise for autosomal dominant polycystic kidney disease

Presented By

Dr Georgios Koukos , Calico Life Sciences, CA, USA

Conference

ERA 2025

Type

Peer-reviewed article

22 August 2025 15:21

Nefecon maintains kidney function regardless of baseline status over 24 months in IgA nephropathy

Presented By

Prof. Jonathan Barratt , University of Leicester, UK

Conference

ERA 2025

Type

Peer-reviewed article

22 August 2025 15:20

Pegcetacoplan is a treatment option for adolescents with C3G or IC-MPGN

Presented By

Dr Antonio Mastrangelo , Policlinico of Milan, Italy

Conference

ERA 2025

Type

Peer-reviewed article

22 August 2025 15:19

Clinical Outcomes in Transplant and Genetic Kidney Diseases

Different Alport Syndrome genotypes lead to different outcomes in terms of kidney function and mortality

Presented By

Dr Katie Wong , University College London, UK

Conference

ERA 2025

Type

Peer-reviewed article

22 August 2025 15:35

Diabetes leads to negative mortality outcomes in kidney transplant patients

Presented By

Dr Laia Oliveras , Hospital Universitari de Bellvitge, Spain

Conference

ERA 2025

Type

Peer-reviewed article

22 August 2025 15:34

Emerging Pathophysiological Mechanisms and Therapeutic Targets

NPT2b could be a new therapeutic target for kidney diseases based on preclinical data

Presented By

Prof. Tzu-Ming Jao , National Taiwan University, Taipei, Taiwan

Conference

ERA 2025

Type

Peer-reviewed article

22 August 2025 15:39

Inhibition of the cGAS/STING pathway has the potential to aid kidney recovery in chronic granulomatous disease

Presented By

Dr Tetsuya Abe , Kitasato University School of Medicine, Japan

Conference

ERA 2025

Type

Peer-reviewed article

22 August 2025 15:36

Featured articles

CONTENTS

Online First

New Frontiers in Cardiorenal Protection: SGLT2 Inhibitors and Emerging Therapies

Late-Breaking Nephrology Studies

ERA’s Top 10 Abstracts

Clinical Outcomes in Transplant and Genetic Kidney Diseases

Emerging Pathophysiological Mechanisms and Therapeutic Targets